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Abstract: Introduction: Trauma is the third most common cause of mortality worldwide and leading cause of death in the 
age group 1 to 44 years. Among those trauma patients, major hemorrhage is responsible for 30 to 40% of mortality, 
despite the fact that it could be preventable and reversible. The ideal resuscitation strategy for trauma patients remains a 
topic of ongoing debate. Transfusion services stress trauma centers with demands for strict accountability for individual 
blood component units and adherence to indications in a clinical field where research has been difficult and guidance 
opinion-based. New data suggest that the most severely injured patients arrive at the trauma center already 
coagulopathic and these patients benefit from prompt specific and corrective treatment. At present, no consensus has 
been reached on ideal fluid for early resuscitation and on the threshold for blood product transfusions. This review article 
provides a brief overview of recent advances in trauma induced hematological complications, role of pathologist in 
managing them and subsequent complicating issues. Thereby, covering the widest possible body of literature. 
Aims and objectives: In this review we address ongoing resuscitation strategies along with potential complications in 
management of the trauma patients. This review also assesses the still ongoing, controversial debate of the best fit 
treatment options. This research is clarifying trauma system requirements for new blood products and blood-product 
usage patterns, but the inability to obtain informed consent from severely injured patients remains an obstacle to further 
research. 
Methods: We considered systematic reviews identified through searches of Cochrane databases from inception to April 
2015 and PubMed up to April 2015. 
Results and Conclusions: Polytrauma patients with severe shock from haemorrhage and massive tissue injury present 
major challenges for management and resuscitation. Many of the current recommendations for damage control 
resuscitation remain controversial. A lack of large, randomized, control trials leaves most recommendations at the level 
of consensus and expert opinion. Ongoing trials and improvements in monitoring and resuscitation technologies will 
further influence how we manage these complex and challenging patients. 
Keywords: Massive hemorrhage, Post injury coagulopathy, Thromboelastography, Damage control resuscitation, 
Transfusion protocols, Trauma center. 
INTRODUCTION 
Trauma is defined as any mechanical damage to 
body caused by external force. It is one of the major 
cause of mortality all over the world. Trauma related 
deaths can be immediate occurring within minutes to 
hours and most of these patients are dead before they 
reach hospital, the major cause being neurological 
injury or massive bleed due to injury to major vessels. 
These account for around half of trauma related 
deaths. Another quarter of patients die during initial 
hours of post injury; they however usually have access 
to trauma care and avoiding mortality among these 
patients is the goal of modern trauma care. Rest of the 
mortality occurs late during the hospital care (1-2 
weeks or more post injury) due to sepsis, multi organ 
failure or other comorbid conditions. There are different 
scores described in literature to categorize trauma 
patients although none is ideal [1]. There should be a 
basic approach to trauma patient in terms of assessing 
airway, breathing, circulation, disability and exposure to  
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rule out any other injury wound. Our discussion will be 
limited to the circulatory part i.e. discussing the trauma 
related hematological changes, their detection, role of 
pathologist in management and subsequent care.  
PHYSIOLOGICAL CHANGES IN TRAUMA 
PATIENTS 
Hemorrhage in trauma patients lead to decreased 
vital organ perfusion which is compensated by 
peripheral vasoconstriction, release of epinephrine and 
activation of rennin angiotensin pathway in an attempt 
to restore perfusion. There is activation of coagulation 
pathway to restrict blood loss; side by side there is 
activation of fibrinolytic pathway, shift of extracellular 
fluid in the circulation thereby diluting coagulation 
factors and thus contributing to trauma induced 
coagulopathy. Traumatic bleeding if not corrected 
timely an adequately by intravenous fluids and blood 
products lead to anemia thus contributing further to 
cardiopulmonary stress [1].
 
An initial workup should include complete blood 
count, blood gas analysis, prothrombin time, partial 
thromboplastin time, fibrinogen level, cross matching 
and serum electrolytes. 
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Adults who loose < 20% of total blood volume do 
well without blood transfusion provided blood volume is 
maintained by administration of crystalloids. Massive 
hemorrhage as defined as transfusion of more than 10 
U of RBCs in 24 hour period is common cause of 
immediate and early deaths in trauma patients. It is in 
these patients the role of blood component support 
emerges. There are several protocols followed by 
transfusion services to provide quick and efficient blood 
product packages to these patients. However, risk of 
transfusion and its benefits to patient should always be 
weighed. RBCs should be used along with intravenous 
fluids to correct volume depletion and anemia [2]. 
Administering blood should be initiated at the scene 
of the accident, thus avoiding the rapid administration 
of i/v fluids (filler fluid) that has been traditionally 
promoted by the advanced trauma life support (ATLS) 
guidelines. This involves giving two liters of crystalloids 
and continuing with packed red blood cells (PRBCs) 
and fresh frozen plasma (FFP) if there was transient or 
no response, with the aim of achieving normotension. 
Nevertheless, it has been noted that the patients 
receiving more preoperative fluid i.e., standard fluid 
resuscitation (SFR) have higher intraoperative and 
overall mortality rate than the restricted fluid 
resuscitation (RFR). The higher mortality rate is 
attributed to the effect of large volume of fluids in 
diluting clotting factors and lowering blood viscosity and 
the raising blood pressure [3]. Limited attempts to 
restore blood pressure improve cardiac output, tissue 
perfusion as well as survival while attempts to restore 
normal tension with crystalloid only results in increased 
hemorrhage and higher mortality [4].  
Morrison et al. demonstrated the lower requirement 
of fluid and blood product transfusion, lower 
postoperative mortality and reduced postoperative 
bleeding and less frequent and less severe 
coagulopathy as evidenced by INR measurements in 
the group managed by hypotensive resuscitation [5]. 
However, same was not found by Dutton et al, [6]
 
who found equal mortality rates amongst patients 
whose fluid therapy was targeted to achieve systolic 
Blood pressure (SBP) > 100 mmHg and 70 mmHg 
respectively.  
This basic dissimilarity in the hemodynamic 
response between controlled hemorrhagic shock (CHS) 
in which the bleeding source has been occluded, and 
uncontrolled hemorrhagic shock (UCHS) in which 
bleeding has temporarily stopped because of 
hypotension, vasoconstriction, and thrombus formation 
also constitutes the basis for fluid resuscitation [7]. 
Recent data has shown improvement in clinical 
outcome when ratio of blood components transfused 
were similar to whole blood. Subsequent reports, 
primarily in the military literature, further support a 
component therapy transfusion in ratios of 1 U RBC/1 
U plasma/1 random donor unit of platelets. However, 
these suffer from survivorship bias and lack adjustment 
for confounding variables such as injury severity [8]. 
Civilian trauma studies have also evaluated the impact 
of more aggressive ratios and noted an association 
with improved survival. Similar to the military data, such 
studies also support using a more aggressive 
RBC/plasma ratio, reporting a significant reduction in 
30-day mortality as compared with those that received 
less plasma. This was independent of age and trauma 
related injury severity score, which by themselves were 
independent predictors of mortality [9]. 
PACKED RED BLOOD CELLS 
Use of RBC transfusion at a hemoglobin level 
above 10 mg/dl is not advocated by various transfusion 
policies ; transfusion is recommended if hemoglobin 
level falls below 6 mg/dl [10]. In addition, there is an 
extensive acceptance of a target value ranging 
between 7 and 10 mg/dl post transfusion [11]. A recent 
comparison between platelet concentrates (PCs) and 
fresh whole blood did not provide a major advantage of 
whole blood versus stored thrombocytes [12]. The risk 
for transmission of infectious diseases or 
microorganisms is clearly higher when fresh whole 
blood is transfused. So, taken together, transfusion of 
fresh whole blood seems to be a reliable strategy in the 
military, but not in the civilian setting [13]. 
GROUP O RED CELLS 
In trauma patients with massive bleeding, it is 
imperative to transfuse blood immediately, and no 
blood bank testing should be attempted before 
emergency transfusion. As group “O” red cells are 
considered universal donar, risk of transfusing group O 
“uncrossmatched” red cells is much lower than the risk 
of patient’s death if blood transfusion is delayed. If a 
patient is to be given uncrossmatched blood, a 
specimen of the patient’s blood should be obtained 
prior to transfusion so that typing and screening can be 
performed while the transfusion is proceeding [2]. Use 
of uncross matched group O red cells in a trauma 
referral unit (TRU) led to decreased survival in patients 
who were increasingly transfused with unmatched 
group O red cells. The safety of using uncross matched 
red cells is occasionally questioned because of the 
possibility of group O donors having high titers of anti-A 
Review of Blood Transfusion Strategies among Trauma Patients Global Journal of Hematology and Blood Transfusion, 2015, Vol. 2, No. 2    35 
or anti-B. While reactions have been reported, the 
incidence and severity of such complications is less 
than that of not receiving blood or the risk of receiving 
red cells of the wrong ABO type in emergency 
situations [14].
 
AUTO-TRANSFUSION 
Autologous blood donation is blood donated by a 
patient, intended for transfusion back into the same 
patient. It may reduce or even eliminate the need for 
allogeneic blood. In autologous blood cell salvage, 
blood lost during or after a surgical procedure is 
salvaged for reinfusion. Use of an auto-transfusion 
device (such as a cell-saver) was found to be well 
tolerated and effective in patients with intra-abdominal 
contamination and hemoperitoneum. Smith and 
colleagues [15] recently noted that intraoperative blood 
salvage is not only well tolerated but that application of 
such devices is associated with a marked decrease in 
the use of banked blood.  
In a randomized controlled trial there was no 
difference in the intra operative blood salvage group 
compared to controls in regards to postoperative 
sepsis, survival, coagulopathy, and requirement for 
clotting factors. To save valuable banked blood, those 
centers with the capability to provide this adjunct 
‘around-the-clock’ should strongly consider the use of 
this important tool in the management of the 
exsanguinating patients [16].
 
TYPES OF INFUSED FLUIDS 
Fluids are the first-line therapeutic approach used 
for resuscitation. In bleeding trauma patients, 
aggressive fluid administration aimed at restoring 
intravascular blood volume is considered as main 
concept of resuscitation. But, by increasing hydrostatic 
pressure on the clots, an aggravation of hypothermia, 
and a further dilution of coagulation factors may 
contribute to further blood loss. 
Crystalloids 
Ringer lactate solution is the most common 
available and used balanced salt solution for fluid 
resuscitation in hemorrhagic shock. It is considered as 
safe as it equilibrates rapidly throughout the 
extracellular compartment, restoring the extracellular 
fluid deficit associated with blood loss. Rhee et al. [17] 
found that solution increases neutrophil superoxide 
burst activity and increased neutrophil adherence. It 
has been shown that aggressive crystalloid 
resuscitation was followed by increased cytokine 
activation including IL-1, IL-6, and TNF [18].
 
The main benefit of ringer lactate solution is that it 
act as a source of bicarbonate due to metabolism of 
lactate to CO2 and H2O; and in contrast to bicarbonate, 
ringer lactate solution does not precipitate calcium 
when it is added to intravenous fluids. Crystalloid 
solutions are relatively inexpensive also. 
Colloid Solutions 
The use of colloid solutions for treatment of 
hemorrhagic shock has been advocated because it 
tends to remain in the intravascular compartment. 
Several colloid solutions including human albumin, 
hydroxyl ethyl starch (HES) and dextran were studied 
in clinical practice. As colloid solutions remain mainly in 
the intravascular compartment, a lower total volume of 
resuscitative fluid is required to attain hemodynamic 
stability compared to crystalloid solutions. However, 
colloid solutions are more expensive, may bind and 
decrease serum ionized calcium, decrease circulating 
levels of immunoglobulines, and may further 
compromise the extracellular fluid volume deficit rather 
than restoring it. Crystalloid and colloid fluid 
resuscitation have been compared by many 
experimental and clinical studies [19]. There is no 
clinical evidence that appropriate resuscitation with 
balanced salt solution is associated with any harmful 
effects on pulmonary function when guided by 
hemodynamic parameters [20]. Although colloid 
solutions do produce transiently greater intravascular 
expansion per unit compared to crystalloid solutions, 
no protective effect of colloid solutions on post-
resuscitation pulmonary function was demonstrated; 
some concerns about the influence of colloids on 
coagulation, renal failure, and pruritus have been 
reported [21]. 
Because of a major concern with regard to 
resuscitation of hemorrhage in the military setting 
where considerable weight and volume of crystalloid 
solutions must be transported in the field sometimes on 
the back of the medical professionals, colloid solutions 
are recommended in military scenarios. This results in 
an inadequate bulk of the ringer's lactate solution that 
is transported to the frontline and thus compromises 
the resuscitation phase in forward areas of deployment. 
Hypertonic Solutions 
Clinical and experimental studies showed that a 
small volume of hypertonic saline (5 ml/kg NaCl 7.5%) 
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with or without dextran can be an effective initial 
resuscitation solution. Hypertonic solutions improve 
micro vascular flow, control intracranial pressure, and 
stabilize arterial pressure and cardiac output with 
small-volume infusion, with no deleterious effects on 
immune functions [22]. 
Trauma Induced Coagulopathy 
This is an important issue concerning physicians as 
well as pathologists. As already discussed injury leads 
to simultaneous activation of coagulation and 
fibrinolytic pathway. Activation of thrombin leads to 
activation of thrombomodulin and subsequent 
activation and consumption of protein C, however this 
occurs in patient with severe injury and hypoperfusion. 
Platelet dysfunction also plays a role. Other 
complication of trauma like acidosis and hypothermia 
also contribute to TIC. Meng et al [23] reported the 
effect of acidosis on coagulation cascade by measuring 
the activity of recombinant factor VIIa on phospholipids 
and platelets. When pH was reduced from 7.4 to 7.0, 
activity of these parameters decreased by 90%. Animal 
studies by Martini et al [24]
 
showed that acidosis 
reduced fibrinogen concentration to 66% ± 2%, 
decreased platelet counts to 49% ± 4%, and decreased 
thrombin generation to 60% ± 4%. PT and PTT were 
found to be prolonged by about 20% due to acidosis. 
Acidosis correction mainly involves restoration of the 
circulation to maintain tissue perfusion. Apart from 
these, resuscitation measures in from of infusion of 
fluids and blood products leads to dilutional 
coagulopathy.  
Currently, there are no accurate methods to assess 
acute trauma coagulopathy so the early empirical 
transfusion of blood and clotting factors are considered 
as best current treatment of coagulopathy [25].
 
Presumably, the extent of injury is great enough in 
these patients to lead to massive consumption of 
coagulation factors, either directly or through activation 
of the protein C pathway. The prevalence of an 
abnormal PT expressed as an international 
normalization ratio (INR), have been shown to increase 
from 5 to 45% and above rising side by side with the 
injury severity score from 5–9. However, the mortality 
rate increased from less than 1% for moderate injury 
and normal INR to more than 80% for severe injury and 
INR of 2.2 or greater. Abnormalities of other 
coagulation tests, such as the activated partial 
thromboplastin time, the fibrinogen concentration and 
the platelet count are less frequent but associated with 
major increases in mortality [26]. 
Monitoring of Coagulation 
Usual diagnostic parameters such as prothrombin 
time (PT), international normalized ratio (INR), and 
activated partial thromboplastin time (APTT) can fail in 
predicting trauma-induced coagulopathy or 
perioperative bleeding complications precisely. These 
coagulation tests cannot recognize disturbances of the 
primary hemostasis (e.g. platelet dysfunction) and 
condition of hyperfibrinolysis. In addition the turn-
around time of these tests is calculated to be between 
30 and 90 min. Establishment of a ‘guide’ by a set 
novel biomarkers and/or easily applicable functional 
assays which allows for decision-making within 
reasonable time (i.e. 10–15 min) is an important aim of 
research in the field of transfusion and coagulation 
management. Monitoring by Rotational elastometer 
(ROTEM) or Thromboelastography (TEG) can be a 
promising approach. In a recent Cochrane analysis, 6 
studies were identified which compared clinical 
judgment and standard laboratory tests or both in the 
adult cardiac surgery and liver transplantation setting 
[24-32]. These research could not found any beneficial 
effect of TEG or ROTEM on patient survival but they 
found a positive effects in pre defined outcomes such 
as reduced bleeding and reduced proportion of patients 
requiring transfusion of platelets or plasma to save the 
cost. Additionally, there were no negative effects or 
adverse events by the application of this Point of care 
(POC) technology. The effects of TEG driven therapy 
need a thorough investigation [28].  
TREATMENT OF TRAUMA INDUCED COAGULO- 
PATHY 
FFP 
Due to dilution, consumption, and inhibition of 
coagulation any major blood loss leads to a 
hypocoagulable state. There is increasing number of 
evidence that early and more aggressive replacement 
of clotting factors reduces mortality and decreases 
transfusion volume [29]. Early standard use of FFP and 
PRBC has been shown rather to prevent than to treat a 
severe dilutional coagulopathy and might contribute to 
an improved survival. However, in patients with already 
clinically relevant factor deficiencies (<50% of activity), 
FFP might not be sufficient to restore coagulatory 
activity immediately. Furthermore, such a strategy 
would result in a high risk of Transfusion associated 
circulatory overload (TACO). Ho and colleagues [30] 
through their mathematical model for FFP transfusion 
strategies have calculated that 1–1.5 units of FFP must 
be given per unit of PRBC just to correct the dilutional 
component of coagulation alone. 
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Fibrinogen 
Massive bleeding leads to loss, consumption, and 
dilution (by volume therapy) of coagulation factors. The 
first factor falling below a critical level is fibrinogen. 
Hiippala et al [31] showed that critical threshold was 
suspected at a level below 100 mg/dl and it was still 
recommended as a trigger for intervention in a 
European Guideline in 2007 [32]. Colloids interfere with 
the measurement of fibrinogen and should always be 
taken into account [33]. FFP is not suitable for a rapid 
increase in already reduced fibrinogen plasma levels.  
Cryoprecipitate 
Cryoprecipitate is a preparation rich in fibrinogen, 
factor VIII, XIII, von Willebrand factor, and fibronectin 
and has been used for therapy of hypofibrinogenemia. 
Typical dose of cryoprecipitate of one unit per 5-10 kg 
body weight is expected to raise fibrinogen level by 
around 70 mg/dl. Murthi et al used increasing amounts 
of cryoprecipitate in one very specific clinical situation: 
the patient with profound, ongoing hemorrhage, severe 
acidosis and established coagulopathy. This is the 
patient in whom efforts to prevent coagulopathy by the 
early use of plasma have failed, either because of 
overwhelming anatomic injury and profound shock 
(e.g., a stab wound to the heart) or pre-existing 
coagulation defects (e.g., end-stage cirrhosis). In these 
circumstances, the concentration of critical clotting 
factors in plasma is too dilute to reverse coagulopathy 
before the patient succumbs to hemorrhagic shock 
[14]. 
Prothrombin Complex Concentrate 
The prothrombin complex concentrate (PCC) 
contains vitamin K-dependent coagulation factors II, 
VII, IX and X, which are essential for the generation of 
thrombin and natural anticoagulants C and S. It is 
extensively used for the therapy of inherited 
coagulation defects or the reversal of vitamin K 
antagonists [34]. 
Factor XIII 
Hemorrhages as well as coagulopathy have been 
shown to cause acquired factor XIII deficiency. Factor 
XIII is used to stabilize the clot by forming covalent 
bonds between fibrin monomers and by cross-linking 
alpha-2 antiplasmin, fibrinogen, fibronectin, collagen 
and other proteins to enhance the mechanical strength 
of the fibrin clot and protect the clot from proteolytic 
degradation [35]. A decreased factor XIII activity leads 
to reduced clot firmness in TEG.  
Hyperfibrinolysis and Inhibition 
All injuries or major surgery might lead to 
hyperfibrinolysis, especially if organs with an increased 
level of plasminogen activators are involved [36]. 
Plasminogen activators are released from hypoxic 
endothelial cells, and plasminogen activator inhibitors 
are proteolysed by antigen-presenting cells. The gold 
standard test for the diagnosis of hyperfibrinolysis is 
the euglobulin lysis time, however the test requires 3 
hours and is thus not feasible in the acute situation. 
The ROTEM platform is based on the principles of TEG 
and has becomes more and more established POC 
method for the detection of hyperfibrinolysis, although it 
does not have a very high sensitivity. 
AB or Low-Titer A Plasma 
The recognition of the acute coagulopathy of trauma 
and the dangers of massive use of crystalloid fluids in 
resuscitation has led to the suggestion that the 
prophylactic administration of plasma along with RBCs 
for initial resuscitation is appropriate in a small number 
of the most severely injured patients identified on the 
basis of rapid ongoing bleeding. Almost one half of 
such patients present to the hospital with deranged INR 
that would be good enough reason to transfuse plasma 
according to conventional transfusion guidelines. The 
core of damage-control resuscitation is beginning 
resuscitation with a 1:1 ratio of plasma to red cells in 
additive solution. This concept when implemented in 
hospitals in Baghdad and Iraq in treating massively 
injured patients markedly reduced coagulopathic 
bleeding, allowing surgeons to operate in less blood-
obscured field. It also reduced tissue swelling and 
organ failure seen postoperatively. When studied 
retrospectively; there was a reduction in mortality from 
66 to 19% in massively injured patients. A group of 
academic trauma centers have now confirmed this 
marked improvement in injury mortality in retrospective 
reviews of their own experience with massive 
transfusion in a combined series of more than 400 
patients [37]. The belief that the most severely injured 
trauma patients should be resuscitated at earliest with 
a mix of red cells and plasma resembling whole blood 
is gaining wide acceptance, even though the optimal 
proportions of RBCs to plasma has not yet been 
defined [38]. 
Platelets 
During acute blood loss, bone marrow and spleen 
release platelets into the circulation, and thereby 
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delaying thrombocytopenia. After transfusion, reverse 
happens: 60–70% of transfused platelets appear 
transiently in the peripheral blood over few days and 
rest fill up the platelet pool. Also an increased ratio of 
platelet concentrate (PC) to PRBCs increase survival 
by 30 days in trauma patients [39].  
Due to progress in noninvasive cardiovascular 
procedures, there are an increasing number of patients 
receiving anticoagulatory therapy mainly targeting 
platelets, e.g. acetyl salicylic acid or glycoprotein IIb/IIIa 
inhibitors. In these patients, platelet transfusions are 
strongly advised in case of active bleeding even at 
higher platelet counts [40]. However, a purely 
prophylactic administration or a continuation after 
bleeding has stopped should be avoided as this might 
increase the rate of thrombosis in these patients. 
Likewise, patients on vitamin K antagonists should 
receive 50 u/ kg PC (prothrombin complex) and 10 mg 
vitamin K intravenously. Early work on blood 
component resuscitation from the Harborview group in 
Seattle suggested that platelets were not a significant 
issue in resuscitation in hemorrhagic shock [41]. The 
fact that hypothermia do play a role in the coagulopathy 
of trauma and platelet function has led to the idea of 
preventing hypothermia during resuscitation which also 
provides sufficient time to obtain a platelet count and 
blood type prior to adding platelets to the early 
transfusion mix [42]. Old work on dilutional 
coagulopathy suggested that many patients required 
platelets after transfusion of two blood volumes. 
However, subsequent studies on seriously injured 
patients suggest that patients receiving platelets early 
have lower rates of coagulopathy and mortality [43]. 
Desmopressin 
Desmopressin by stimulation of extra renal V2 
receptors and mobilization of thrombocytes from the 
bone marrow, [44] leads to the release of factor VIII 
and von Willebrand factor from the endothelium. It has 
been used if the patient is suffering from uremia, 
hepatic disease, or on aspirin but the efficacy is limited 
and inconsistent. Development of hypertension is one 
of the major side effects. Tachyphylaxis may be seen in 
some cases, but can be avoided if application is limited 
to <24 h [45]. 
TRANSFUSION ASSOCIATED ISSUES AND ROLE 
OF LABORATORY 
Blood Transfusion can be associated with certain 
complications like immunologic and nonimmunologic 
reaction and various infections. 
A. Immunological reaction can be as following; 
1. Alloimmunization to red cell antigens, HLA 
antigen, platelets specific antigens and 
neutrophil specific antigens. The risk of red cell 
alloimmunization has been estimated at 1.0% to 
1.4% per unit transfused [2]. If Rh-D positive red 
cells or platelets are given to a woman of 
childbearing age, it may be possible to prevent 
alloimmunization with the administration of Rh 
immunoglobulin. If she is clinically stable and 
heavily exposed, it may even be appropriate to 
perform red cell exchange by apheresis before 
administration of Rh immunoglobulin [45]. If 
alloantibodies were detected in the initial 
antibody screen and ignored in an initial urgent 
or massive transfusion, the possibility of a 
delayed hemolytic transfusion reaction must be 
considered and the care team notified.  
2. Hemolytic transfusion reactions due to 
development of antibodies capable of reacting 
with red cell antigens may lead to red cell 
destruction usually involving transfused rather 
recipient blood. These reaction can cause 
immediate (intravascular) or delayed transfusion 
reaction [2]. A review of fatal hemolytic reactions 
said 86% were caused by ABO incompatibility 
and of these 89% were caused by simple clerical 
error [47]. Patients with major hemolytic 
transfusion reactions should be assessed for 
possible presence of intravascular coagulation. 
Their renal functiontests, urinary haemosiderin or 
free hemoglobin should be detected. 
Demonstration of methmalbuminema, reduced 
serum haptoglobin or hyperbilirubinemia may 
provide supportive evidence. Delayed haemolytic 
transfusion reactions (DHTR) are generally mild 
and show extravascular haemolysis. If a DHTR 
is suspected, direct antiglobin test should be 
done and if positive, antibody should be eluted 
from the red cells and identified [2]. 
3. Febrile non hemolytic transfusion reactions 
(FNHTR) have been reported in patient receiving 
transfusion, ranging from 0.5% to 3.0%. This is 
attributed to alloimmunization to leukocytes and 
platelets antigens. HLA antibodies are most 
commonly found, followed by platelet-specific 
antibodies and granulocyte-specific antibodies. 
Cytokines derived from leucocytes which get 
accumulated during blood product storage 
especially platelet concentrates which are stored 
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at room temperature are another main reason 
behind pathogenesis of FNHTR. The 
complication can be avoided by use of 
leucoreduced red cells [2]. 
4. Transfusion related acute lung injury (TRALI)- is 
the most frightening adverse effect of blood 
transfusion. The incidence of TRALI is much 
lower (~1:10,000) than that of other adverse 
effects such as severe febrile or allergic 
reactions (~1%); however, TRALI is a life 
threatening complication with urgent need of 
mechanical ventilation in most cases [48]. 
Diagnosis of TRALI is based on acute lung injury 
within 6 hours of transfusion. Acute lung injury 
shows hypoxemia, bilateral chest infiltrate on X-
ray and no evidence of circulatory overload. Its 
management involves supportive measures and 
hemodynamic monitoring [2]. It is mainly 
associated with transfusion of plasma extracted 
from female donors. This is supported by the fact 
that incidence of TRALI was significantly 
reduced since plasma from women after 
pregnancy and/or child birth were excluded from 
the donor pool to avoid the transmission of 
antibodies with specificity mainly against human 
neutrophil antigens (HNA) or human leukocyte 
antigens (HLA). A further reduction might also be 
reached by the use of lyophilized plasma [48].  
5. Allergic transfusion reactions are commonly 
seen in 1% to 3% of transfusion recipient. Whole 
blood and plasma are more likely to cause them 
rather concentrated red cells. If these are not 
controlled by medication; use of product with 
reduced plasma content, washed RBC and IgA 
deficient blood product can be an alternative 
option [2]. 
6. Post transfusion purpura can cause life 
threatening thrombocytopenia 5 to 10 days after 
transfusion. The management includes high 
dose IVIG, corticosteroids or plasma exchange 
[2]. 
7. Transfusion related imunomodulatory effects 
(TRIM) - allogeneic blood transfusion results in 
the transfer of not only RBCs, but also significant 
amounts of potential immunoeffector cells, their 
products (cytokine) and various substances that 
may be seen by the host immune system as 
foreign antigens [2].  
8. Transfusion associated graft versus host disease 
(GVHD) is seen due to viable immune competent 
T lymphocytes. High risk for GVHD are patients 
undergoing BMT, patients receiving granulocyte 
and HLA matched platelet transfusion, 
transfusion from blood relatives, congenital 
immunodeficiency and Hodgkin’s lymphoma [2]. 
9. Microchimerism is the presence of a small 
number of cells that originate from another 
individual and are therefore genetically distinct 
from the cells of the host individual. This 
phenomenon may be related to certain types of 
autoimmune diseases. The trauma and 
transfusion groups at the University of California, 
Davis (CA, USA), have shown that transfused 
trauma patients have a significant incidence of at 
least a transient transfusion-related 
microchimerism that can range from 10 to more 
than 50% of population. It appears to have the 
potential to persist in approximately 5% of 
affected individual for as long as up to a period 
of decades [49]. Microchimerism appears to 
occur when donor and recipient have closely 
matched HLA alleles. At this point, there do not 
appear to be chronic immunologic consequences 
of this finding [50]. 
B. Non immunological adverse effects; 
1. Transfusion associated circulatory overload 
(TACO) is seen due to transfusion of red cell 
preparations or plasma products. To prevent 
these reactions transfusion should be 
administered slowly at the rate of 1 to 2ml blood 
per Kg of body weight per hour in close 
observation.  
2. Massive transfusion may cause metabolic effects 
because stored blood differs in its composition 
from the circulating blood in the body. The 
elevated potassium content of stored red cells 
rarely leads to hyperkalemia but it is a risk in the 
presence of renal failure, shock with acidosis or 
hemolysis. Plasma contains increased citrate 
which may leads to hypocalcemia. Hypothermia 
may occur specially in neonates and elderly or 
particularly sensitive to these reactions. It may 
leads to arrhythmia and may interfere in platelets 
functions and clotting. Dilution coagulopathy may 
leads to abnormal PT, APTT and 
thrombocytopenia.  
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C. Currently the blood transfusions can roughly be 
categorized as noninfectious because transfusion-
transmitted infections by HBV, HCV or HIV are actually 
very rare events as proved by the German 
Hemovigilance System [43]. In 1999,nucleic acid 
testing (NAT) for HIV and HCV RNA was added to 
blood donor screening. Infectious disease testing 
usually involves screening for Hepatitis B, hepatitis C, 
HIV-1/2, HTLV I/II, and syphilis. Other infections which 
can circulate in the blood of an apparently healthy 
donor are hepatitis A, delta virus, west nile virus, 
cytomegalo virus, dengue virus, parasites including 
malaria, babesia and trypanosome cruzi, variant of 
Creutzfeldt-Jakob disease and bacterial contamination. 
Pathogen reduction technology  
Donor screening and testing cannot completely 
eliminate the possibility of transfusion transmitted 
infections. Pathogen reduction technology for 
transferable blood component is a technique which 
should ideally inactivate residual pathogens without 
adversely affecting the functions, toxicity or 
immunogenicity of the blood components. Most 
commercial plasma derivatives are treated with heat 
and /or organic solvents and detergents and cellular 
blood components are added with additives that bind to 
and damage DNA of residual pathogens. There is 
concern that DNA altering agents can cause long term 
toxicity in transfusion recipient, requiring further work in 
this area [2].  
LIMITING BLOOD PRODUCT EXPOSURE 
The Transfusion Requirements in Critical Care trial 
showed that hemodynamically stable intensive care 
patients, including many trauma patients did not need 
red cell transfusion and neither had they appeared to 
benefit from it. 
52
 Many retrospective studies suggest a 
relationship between the administration of blood 
products and the incidence of multiple organ failure but 
are unable to distinguish statistically between the 
possible adverse effects of the blood itself and 
transfusion as a marker of worse injury [53]. However, 
misidentification of donors, recipients with acute 
hemolytic transfusion reactions, administration of 
bacterially contaminated blood products and TRALI are 
all associated with transfusion-related deaths each 
year in the USA and Britain [54]. 
To reach a homeostasis between dilutional 
coagulopathy and the risk of rebleeding, the 
cardiovascular consequences of traumatic anemia and 
the risk of transfusion-related adverse events remains 
both difficult and obscure. Currently, the best resort to 
cope up with this issue is early evaluation and 
management of the coagulopathy of trauma thereby 
decreasing the need for massive transfusion and its 
attendant risks. 
CONCLUSION  
Fortunately, only a small percentage of trauma 
patients will require massive transfusion. But, in these 
patients there is a significant trauma-induced 
coagulopathy which is aggravated secondarily by 
dilution and consumption of coagulation factors and 
platelets, requiring interdisciplinary teamwork.  
The implementation of a well-structured worksheet 
and standard operating procedures with clearly 
allocated tasks and therapeutic options is necessary to 
improve the clinical outcomes of patients with life-
threatening massive hemorrhage.  
These patients should benefit from the optimal 
management of fluid resuscitation, blood transfusion 
(early change to a fixed ratio of FFP:PRBCs of 1:1), 
and the treatment of trauma-induced coagulopathy. 
The use of recombinant factor VIIa is only justified if 
replacement therapy of blood components and 
coagulation factors fails to cease major bleeding. 
Only 2% of civilian trauma patients and 8% of 
military casualties are likely to require massive 
transfusion and therefore are likely to benefit from 
greater exposure to plasma and other blood products. 
Severe injury, shock and evidence of rapid or 
uncontrollable bleeding are the clinical indicators that 
suggest the need for the early use of plasma to prevent 
coagulopathy. After acute resuscitation, conservative 
blood guidelines should apply. Better tools for 
hemorrhage control and physiologic assessment are 
needed.  
Whilst massive hemorrhage continues to be a major 
cause of mortality, it is often reversible, and can be 
adequately managed by early identification of source of 
their bleeding, approaching them with consideration of 
diagnosis, prevention and treatment of the lethal triad 
and damage control surgery to stop the bleeding. 
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